H. Mizuhara, M. Uno, N. Seki, M. Yamashita, M. Yamaoka, T. Ogawa, K. Kaneda, T. Fujii, H. Senoh and H. Fujiwara, “Critical Involvement of Interferon Gamma in the Pathogenesis of T-Cell Activation-Associated Hepatitis and Regulatory Mechanisms of Interleukin-6 for the Manifestations of Hepatitis,” Hepatology, Vol. 23, 1996, pp. 1608-1615.

has been cited by the following article:

• TITLE: Manganese Superoxide Dismutase Therapy in a Murine Hepatitis-Associated Injury

  AUTHORS: Yan Li, Nathaniel P. Reuter, Xuanshe Li, Robert Calvin Grier Martin

  KEYWORDS: Carcinogenesis, Hepatocellular Carcinoma, Chemoprevention, Mntbap

  JOURNAL NAME: Journal of Cancer Therapy, Vol.2 No.3, August 24, 2011

  ABSTRACT: We aim to test the hypothesis that Con A-induced hepatitis and cell death can be prevented by the administration of the MnSOD mimetic MnTBAP. Male C57 mice were divided into 3 groups, 1) pretreated with MnTBAP (30 mg/kg) for 2 days and then Concanavalin A (Con A) (15 mg/kg); 2) pretreated with saline for 2 days and then Con A (15 mg/kg); 3) was the control treated with saline for 3 days. Extensive hepatic necrosis, with a significant increase in apoptosis, lipid peroxidation and decreased MnSOD enzymatic activity was found in the hepatic tissue of Con A-treated mice with significantly attenuation of all factors by pretreatment with MnTBAP. MnTBAP protected hepatocytes from Con A-induced hepatic injury with less degree of liver inflammation—ConA + MnTBAP (2.1 ± 0.4) vs. Con A (2.6 ± 0.3)—and significantly less cell death (1.2 ± 0.3 vs. 2.7 ± 0.4, p = 0.03). MnSOD supplementation attenuated the oxidative-induced stress effects of Con A-induced injury and the protective effects of MnSOD supplementation against Con A-induced hepatitis could be through its anti-oxidative properties. Further evaluation of MnSOD manipulation could have the potential to prevent ongoing hepatic injury in hepatitis.